The aforementioned studies involving genetic manipulation of AhR thus indicated that the activation of AhR will aggravate the NAFLD pathology, whereas inhibition of AhR signaling using AhR antagonists will alleviate NAFLD in pre-clinical models. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.